Bio-Techne Corporation
TECH Healthcare Biotechnology NASDAQ
$61.68
$-1.86 (-2.93%)
Open: $63.50 | High: $63.98 | Low: $61.50 | Prev Close: $63.54
Market Cap: $9.67B
Volume: 1.6M | Avg: 2.2M
Last updated: December 05, 2025 at 10:06 PMInvestment Rating
Neutral
Overall Score: 60/100
Rating Breakdown:
Stock Score Analysis
Stock Score: 485
Comprehensive Quality Assessment
Component Breakdown:
Valuation Metrics
| P/E Ratio | 125.88 |
| P/B Ratio | 4.82 |
| P/S Ratio | 7.95 |
| EPS | $0.49 |
| Beta | 1.47 |
| Shares Outstanding | 156.75M |
| 52-Week High | $79.28 |
| 52-Week Low | $46.01 |
| SMA 50 | $60.73 |
| SMA 200 | $55.48 |
| Dividend Yield | 0.52% |
| Annual Dividend | $0.32 |
| Next Earnings | February 03, 2026 12:00 PM ET |
Financial Ratios
| Gross Margin | 65.4% |
| Operating Margin | 9.0% |
| Net Margin | 6.4% |
| ROE | 3.9% |
| ROA | 3.1% |
| Debt/Equity | 0.19 |
| Current Ratio | 4.22 |
| Quick Ratio | 2.81 |
Balance Sheet
| Total Assets | $2.56B |
| Total Liabilities | $639.06M |
| Total Equity | $1.92B |
| Cash | $162.19M |
| Total Debt | $444.06M |
| Net Debt | $281.87M |
Income Statement
| Revenue | $1.22B |
| Gross Profit | $790.27M |
| Operating Income | $102.25M |
| Net Income | $73.40M |
| EBITDA | $216.88M |
| Revenue/Share | $7.83 |
Cash Flow
| Operating CF | $287.56M |
| CapEx | $31.01M |
| Free Cash Flow | $256.55M |
| Book Value/Share | $12.80 |
| Tangible Book/Share | $4.25 |
| Equity/Share | $12.80 |
Technical Indicators
| RSI (14) | 59.28 Neutral |
| MACD |
1.05
Signal: 0.79
|
| Volatility | 35.65% |
| Trading Signal | Bullish |
Performance & Returns
| 1 Year | -6.26% |
| Sharpe Ratio | 0.04 Fair |
| Volatility (Ann.) | 45.6% High Risk |
| TECH (1Y) | -6.26% |
| S&P 500 (1Y) | +11.86% |
| Alpha (Excess Return) | -18.12% |
Sector Comparison (Healthcare)
| Metric | TECH | Sector Avg | Percentile |
|---|---|---|---|
| P/E Ratio | 125.88 | 29.57 | 95% |
| P/B Ratio | 4.82 | -0.64 | 67% |
| ROE (%) | 3.90% | 9.90% | 20% |
| Net Margin (%) | 6.41% | 10.11% | 30% |
| Stock Score | 485 | 504.0 | 32% |
| 1Y Return (%) | -6.26% | +4.61% | 31% |
Historical Price Analysis (Last 200 Days)
Technical Analysis
| Ticker | Close | SMA 5 | SMA 8 | SMA 13 | SMA 50 | SMA 200 | RSI (14) | MACD | Volatility (%) | Volume | Signal | SMA Decision |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TECH | $61.68 | $63.72 | $64.07 | $62.11 | $60.73 | $55.48 | 59.28 | 1.05 | 35.65% | 1442714 | Weak Short | Price Below SMAs |
Candlestick Patterns
There wasn't any recognizable pattern for the TECH stock
News Sentiment
| 📊 Ticker | 📰 Headline | 💭 Sentiment | 📡 Source | 🔗 URL |
|---|---|---|---|---|
| TECH | Bio-Techne Corporation (TECH) Presents at Citi Annual Global Healthcare Conference 2025 Transcript | Neutral | seekingalpha.com | Read More |
| TECH | Bio-Techne Corporation (TECH) Presents at Evercore 8th Annual Healthcare Conference Transcript | Neutral | seekingalpha.com | Read More |
| TECH | CMB.TECH NV (CMBT) Q3 2025 Earnings Call Transcript | Neutral | seekingalpha.com | Read More |
| TECH | CMB.TECH announces Q3 2025 results | Neutral | globenewswire.com | Read More |
| TECH | Bio-Techne to Present at Upcoming Investor Conferences | Neutral | prnewswire.com | Read More |
Company Information
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
| CEO | Kim Kelderman |
| Employees | 3100 |
| Country | US |
| IPO Date | 1989-02-09 |
| Exchange | NASDAQ |
| Website | https://www.bio-techne.com |
| Sector | Healthcare |
| Industry | Biotechnology |
Similar Stocks (Healthcare - Biotechnology)
Rating Metrics Explained
DCF Score (Discounted Cash Flow)
Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.
ROE Score (Return on Equity)
Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.
ROA Score (Return on Assets)
Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.
D/E Score (Debt-to-Equity)
Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.
P/E Score (Price-to-Earnings)
Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.
P/B Score (Price-to-Book)
Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.
Rating Recommendations:
Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:
-
Strong Buy (5/5): Excellent score - strong positive indicator
- The metric significantly outperforms industry averages (top 20% of companies)
- Indicates exceptional financial health or attractive valuation in that category
-
Buy (4/5): Good score - positive indicator
- Above-average performance (top 40% of companies)
- Shows strong fundamentals with room for improvement
-
Neutral (3/5): Average score - neutral indicator
- Performance in line with industry median (middle 20%)
- Neither significantly positive nor negative signal
-
Sell (2/5): Below average - negative indicator
- Below-average performance (bottom 40% of companies)
- Suggests weakness in this particular metric
-
Strong Sell (1/5): Poor score - strong negative indicator
- Significantly underperforms industry (bottom 20%)
- Indicates potential risk or overvaluation in that category